HK Stock Market Move | INNOVENT BIO (01801) rises over 2%; partner Ollin to be acquired by Johnson & Johnson; core Phase III asset IBI/OLN324 to be incorporated into J&J's pipeline.

date
10:51 19/11/2026
avatar
GMT Eight
Innovent Biologics (01801) rose over 2%. As of press time, it was up 1.68% at HK$84.9, with turnover of HK$255 million.
INNOVENT BIO (01801) rose over 2%, up 1.68% as of press time to HK$84.9, with turnover of HK$255 million. On the news front, Johnson & Johnson recently announced the acquisition of Ollin Biosciences for US$2.2 billion in upfront payment, plus up to approximately US$1.125 billion in regulatory and commercial milestone payments, for a total transaction value of up to US$3.325 billion. UBS noted that INNOVENT BIO's partner Ollin will be acquired by Johnson & Johnson, and the core Phase III asset IBI/OLN324 (Ang2/VEGF) will be incorporated into J&J's pipeline, a view the bank holds positively. UBS believes the transaction affirms INNOVENT BIO's strength in ophthalmology R&D, including the US$2.2 billion upfront payment and up to US$1.125 billion in milestone payments. IBI/OLN324's Phase 1b clinical data in wAMD/DME are positive relative to faricimab. Blackstone will pay Johnson & Johnson US$750 million to fully fund the Phase III clinical trial of OLN324, in exchange for certain milestones and single-digit royalties.